Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Jordan's pharmaceutical sector has emerged as a regional leader in branded generics, with exports reaching 85 global markets and contributing 5% to total industrial exports[11]. The industry achieved a 14.8% export growth in 2024 despite regional challenges, totaling JD611 million[11], while maintaining 80% production capacity for international markets[5][9].

Market Assessment

Branded Generics Dominance:

• Represents 90% of Jordan's pharmaceutical output[7]
• Key therapeutic areas: Chronic diseases, oncology, and infectious treatments[11]
• Major exporters: Hikma Pharmaceuticals ($2B global generic sales)[9], JPM, and others serving 85 countries[11]

Export Performance:

• 19% growth Q1-Q3 2024 (JD437M)[5]
• Top destinations: Saudi Arabia, Iraq, UAE, and U.S.[5][11]
• Production capacity: JD1.5B annually across 4,500 products[11]

Supply Chain Dynamics:

• 70% profit from re-exporting Western drugs[1]
• Heavy API import dependence (€60-80M annual)[3]
• Workforce: 7,000 employees (35% female)[11]

Regulatory Opportunities

Accelerated Approvals:

• 30-60 day fast-track for EMA/USFDA-approved drugs[2][12]
• Priority registration for first 3 generics[6]
• GCC harmonization through Central Drug Registration system[2]

Strategic Partnerships:

• WHO/JFDA collaboration to strengthen PV systems[10]
• IFC-supported modernization initiative (2023)[5]
• EMA-aligned quality standards for biosimilars[2][4]

Market Expansion Enablers:

• Economic Modernisation Vision targets:
  • 20.3% annual export growth through 2033[11]
  • JD1.7B GDP contribution (+217% from 2021)[11]
  • 16,000 pharma jobs by 2033[11]

Key Challenges

Regulatory Hurdles:

• Fragmented MENA approvals (60+ authorities)[2]
• Counterfeit drug risks in regional markets[2][6]
• Compliance costs for USFDA/EU GMP certifications[7]

Market Pressures:

• Arab neighbors developing domestic production[7]
• TRIPS agreement impacts from India/Egypt[7]
• Price harmonization demands in GCC markets[2]

Innovation Gaps:

• R&D investment <8% of sales[1][7]
• No originator drug development pipeline[1]
• Technology limitations in advanced drug forms[3]

Strategic Outlook

The JFDA's new pharmacovigilance framework and digital transformation initiatives position Jordan to capitalize on growing biosimilar demand[4][10]. With 80% production already export-focused, the sector aims to penetrate European markets through WHO benchmarking programs while addressing API dependency via JD1.1B EMV investment targets[11][7]. Success hinges on balancing GCC price controls with innovation incentives in smart packaging and biologics[12][13].

"Our collaboration with WHO ensures Jordan remains the region's pharmacy hub through cutting-edge regulation." - Dr. Nizar Mahidat, JFDA Director[10]

Key statistics:

• 2024 exports: 19% growth to Saudi Arabia[5]
• 35% female workforce participation[11]
• 85 global markets served[11]

References

1. https://www.giz.de/de/downloads/Value%20Chain%20Analysis%20of%20the%20Pharmaceutical%20Sector%20in%20Jordan.pdf
2. https://www.delveinsight.com/blog/the-regulatory-process-for-drug-approval-in-the-mena-region
3. https://aumet.com/en/pharmaceutical-market-in-jordan/
4. https://www.eminencegroupco.com/ensuring-pharmaceutical-safety-in-jordan/
5. https://jordantimes.com/news/business/kingdoms-pharmaceutical-industry-grows-19-2024-national-products-reach-80-markets
6. https://faolex.fao.org/docs/pdf/jor180732E.pdf
7. https://uiti.org/research/pdf/plc.pdf
8. https://www.jfda.jo/Pages/viewpage.aspx?pageID=362
9. https://dai-global-developments.com/articles/now-more-competitive-jordans-pharmaceuticals-see-healthy-jump-in-exports/
10. https://jordan.un.org/en/260794-who-gov%E2%80%99t-hold-dialogue-strengthen-regulatory-system-enhance-pharmaceutical-production
11. https://jordantimes.com/news/business/jordans-pharmaceutical-exports-grow-148-2024-overcoming-regional-challenges
12. https://www.theinsightpartners.com/reports/branded-generics-market
13. https://credevo.com/articles/2024/02/25/generic-drug-market-in-the-asia-pacific-region-regulations-challenges/